Pataxel concentrate for infusion – paclitaxel for ovarian, breast and lung cancer and Kaposi's sarcoma
Pogledajte blok ispod gde možete pronaći proizvode koji su slični ili imaju slična dejstva kao proizvod na čijoj se stranici nalazite.
- Stock: Zabrana online prodaje
- Brand: VIANEX S.A.
- Model: BR-671654156
Pataxel is a cytostatic medicine containing paclitaxel – a medicine from the taxane group that prevents the growth and division of certain tumour cells. It is given as an intravenous infusion in hospital, under the supervision of a doctor experienced in chemotherapy.
It is authorised as a concentrate for solution for infusion of 6 mg/mL, in vials of 30 mg/5 mL, 100 mg/16.7 mL and 300 mg/50 mL. It is used to treat ovarian cancer, breast cancer, advanced non-small cell lung cancer and AIDS-related Kaposi's sarcoma.
Important warning
- Dispensing status: the medicine is used only in inpatient healthcare institutions.
- Before each infusion premedication (corticosteroid, antihistamine and H2 antagonist) is mandatory to prevent severe allergic reactions, which may be fatal.
- It must not be given to people with low white blood cell or platelet counts, severe liver impairment, or to breast-feeding women.
- The medicine contains 49.7% vol ethanol (up to 21 g per average dose) and macrogolglycerol ricinoleate (polyoxyl castor oil).
- This page is for information only and is not an offer to buy the medicine online.
What is Pataxel used for and how is it given?
Key information about the medicine
| Name of the medicine | Pataxel, concentrate for solution for infusion (30 mg/5 mL, 100 mg/16.7 mL, 300 mg/50 mL) |
|---|---|
| Active substance | paclitaxel |
| Strength | 6 mg paclitaxel per 1 mL of concentrate |
| Pharmaceutical form | concentrate for solution for infusion – clear, slightly yellow solution |
| Therapeutic group | antineoplastic agents – taxanes (ATC L01CD01) |
| Pack | 1 glass vial of 5 mL, 16.7 mL or 50 mL |
| Marketing authorisation holder / manufacturer | Beocompass d.o.o. Belgrade; manufacturer Vianex S.A. – Plant C', Pallini, Greece |
| ALIMS authorisation number | 515-01-02794-21-001 (30 mg), 515-01-02795-21-001 (100 mg) and 515-01-02796-21-001 (300 mg) of 08.09.2022 |
| Dispensing status (Serbia) | SZ – for use only in inpatient healthcare institutions |
What is Pataxel used for?
- Ovarian cancer: first-line chemotherapy of advanced cancer or residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin; second line in metastatic cancer after failure of platinum-containing therapy.
- Breast cancer: adjuvant treatment of node-positive cancer after anthracycline and cyclophosphamide (AC) therapy; first line in locally advanced or metastatic cancer in combination with an anthracycline or with trastuzumab (in HER2 overexpression); monotherapy of metastatic cancer when anthracycline therapy has failed or is not suitable.
- Advanced non-small cell lung cancer: in combination with cisplatin, in patients who are not candidates for potentially curative surgery and/or radiotherapy.
- AIDS-related Kaposi's sarcoma: advanced disease after failure of liposomal anthracycline therapy.
How is Pataxel given?
The medicine is prepared and given by hospital staff as an infusion into a vein through an in-line filter with a microporous membrane (≤ 0.22 micrometres). The dose depends on the disease, body surface area (mg/m²), blood test results and tolerance of previous doses – usually between 100 and 220 mg/m², as a 3- or 24-hour infusion, every 2–3 weeks.
| Ovarian cancer – first line | 175 mg/m² over 3 hours, followed by cisplatin 75 mg/m², every 3 weeks; or 135 mg/m² over 24 hours, followed by cisplatin 75 mg/m², every 3 weeks |
|---|---|
| Ovarian cancer – second line | 175 mg/m² over 3 hours, every 3 weeks |
| Breast cancer – adjuvant | 175 mg/m² over 3 hours, every 3 weeks, 4 cycles after AC therapy |
| Breast cancer – first line | with doxorubicin (50 mg/m², given 24 hours earlier): 220 mg/m² over 3 hours, every 3 weeks; with trastuzumab: 175 mg/m² over 3 hours, every 3 weeks |
| Breast cancer – second line | 175 mg/m² over 3 hours, every 3 weeks |
| Non-small cell lung cancer | 175 mg/m² over 3 hours, followed by cisplatin 80 mg/m², every 3 weeks |
| AIDS-related Kaposi's sarcoma | 100 mg/m² over 3 hours, every 2 weeks |
- Premedication: dexamethasone, diphenhydramine (or another antihistamine) and cimetidine or ranitidine, before each infusion.
- With cisplatin, Pataxel is given before cisplatin; with doxorubicin, 24 hours after doxorubicin.
- The next dose is given only when neutrophil and platelet counts have recovered; after severe neutropenia or severe peripheral neuropathy the dose is reduced by 20% (by 25% in Kaposi's sarcoma).
- Tell the nurse immediately if you feel pain at the injection site during or after the infusion – the medicine may be leaking outside the vein.
Special patient groups
- Children and adolescents under 18 years: use is not recommended (no data on efficacy and safety).
- Impaired liver function: must not be used in severe impairment; there are no adequate data on dose adjustment in mild to moderate impairment.
- People with liver disease, epilepsy or alcoholism: caution is needed because of the alcohol content.
Contraindications – when the medicine must not be used
- allergy to paclitaxel, macrogolglycerol ricinoleate (polyoxyl castor oil) or any of the excipients;
- breast-feeding;
- low white blood cell or platelet counts (checked by blood tests);
- serious, uncontrolled infection in patients treated for Kaposi's sarcoma;
- severe liver impairment.
Precautions and warnings
- marked allergic reaction (shortness of breath, dizziness due to low blood pressure, facial swelling, rash) – some reactions may be fatal;
- heart disease or liver problems; abnormal blood cell counts;
- irregular heartbeat, dizziness or fainting during treatment;
- tingling, burning or numbness of the fingers and toes (peripheral neuropathy);
- simultaneous radiotherapy of the lungs – lung inflammation may occur;
- diarrhoea during or soon after treatment – possible inflammation of the colon;
- in Kaposi's sarcoma – mouth ulcers or inflammation of the mouth;
- blood tests and heart function tests may be needed before treatment; the infusion site is monitored carefully.
Interactions with other medicines
Tell your doctor about all medicines you are taking, especially:
- antibiotics (e.g. erythromycin, rifampicin) and antifungals (e.g. ketoconazole);
- antidepressants (e.g. fluoxetine);
- medicines for epilepsy (e.g. carbamazepine, phenytoin);
- medicines to lower blood lipids (e.g. gemfibrozil);
- medicines for heartburn or ulcers (e.g. cimetidine);
- medicines for HIV/AIDS (e.g. ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, nevirapine);
- clopidogrel (a medicine to prevent blood clots).
The amount of alcohol in the medicine may affect the action of other medicines.
Pregnancy, breast-feeding and fertility
- Pregnancy: must not be used during pregnancy unless clearly advised, as it may cause birth defects. The patient and/or partner must use reliable contraception during treatment and for 6 months afterwards; report a pregnancy to the doctor immediately.
- Breast-feeding: must not be used during breast-feeding – breast-feeding is stopped during treatment.
- Fertility: Pataxel may cause infertility, which may be permanent; men are advised to ask about freezing and storing sperm before treatment.
Driving and using machines
- The alcohol in the medicine and side effects such as dizziness, nausea and fatigue may impair the ability to drive and use machines immediately after treatment.
Possible side effects
According to the leaflet, all side effects should be reported to the doctor immediately, as they may be serious.
- Very common: weakness, pain or loss of sensation in the arms and legs, tingling and pins and needles in the hands and feet (may last longer than 6 months after treatment); infections (most often of the urinary and upper respiratory tract); bone marrow suppression with anaemia, neutropenia, thrombocytopenia and leukopenia; low blood pressure; muscle and joint pain; hair loss (marked in most patients, usually in the first month); nausea and vomiting; mild diarrhoea; mouth ulcers and mucosal inflammation; mild allergic reactions with flushing and rash.
- Common: slow heartbeat; infusion-site reactions (swelling, pain, redness, hardening, leakage outside the vein with cellulitis); temporary changes to nails and skin; abnormal liver function tests.
- Uncommon: heart rhythm disorders, heart attack, cardiomyopathy; severe infection and sepsis with shock; thrombosis and thrombophlebitis; high blood pressure; severe allergic reactions; jaundice.
- Rare and very rare: anaphylactic reactions; pneumonia, pulmonary fibrosis and embolism; peritonitis; motor neuropathy; pancreatitis; heart failure; Stevens-Johnson syndrome and toxic epidermal necrolysis; seizures, encephalopathy; severe liver damage; hearing loss, ringing in the ears; visual disturbances; pseudomembranous colitis; loss of nails; acute leukaemia or myelodysplastic syndrome.
- Not known: tumour lysis syndrome; macular oedema and visual disturbances; scleroderma; systemic lupus erythematosus; disseminated intravascular coagulation; redness and swelling of the palms and soles with peeling skin.
Overdose and missed dose
- Overdose: unlikely, as the medicine is given by hospital staff; if you have doubts about your dose, tell your doctor.
- Treatment schedule: the oncologist decides on cycle dates, postponement or dose adjustment based on blood tests and tolerance.
When to seek medical help immediately?
- difficulty breathing, wheezing, swelling of the face, lips or throat, dizziness during or after the infusion;
- fever, shivering or signs of infection after a treatment cycle;
- chest pain, irregular heartbeat, fainting;
- severe or bloody diarrhoea, severe abdominal pain;
- pain, swelling or redness at the infusion site; blistering and peeling skin.
Pharmacist's advice
Before each treatment cycle attend your scheduled blood tests and tell your doctor about all medicines and products you take, including medicines for epilepsy, antidepressants, antibiotics and clopidogrel.
After the infusion monitor your body temperature – a fever with a low white blood cell count requires urgent examination. Because of the alcohol in the medicine, do not drive straight after treatment.
Report tingling and numbness in your fingers and toes to your oncologist early, as the dose may need to be adjusted.
Availability and price
Pataxel is a medicine used only in inpatient healthcare institutions. ApotekaOnline.rs does not sell prescription or hospital medicines online, and this page is for information only.
Discuss the treatment with your oncologist.
Related information
For more information on the treatment, talk to your oncologist or pharmacist and follow the approved package leaflet.
Composition, pack and manufacturer
- Active substance: paclitaxel 6 mg/mL – 30 mg in 5 mL, 100 mg in 16.7 mL or 300 mg in 50 mL of concentrate.
- Excipients: macrogolglycerol ricinoleate (polyoxyl castor oil), anhydrous ethanol, anhydrous citric acid.
- Pack: colourless glass vial (type I) with a butyl rubber stopper, aluminium ring and flip-off cap; 1 vial per box.
- Marketing authorisation holder: Beocompass d.o.o. Beograd, Zvečanska 60/22, Belgrade; manufacturer: Vianex S.A. – Plant C', 16th km Marathonos Ave, Pallini, Attiki, Greece.
- Authorisations: 515-01-02794-21-001 (30 mg/5 mL), 515-01-02795-21-001 (100 mg/16.7 mL) and 515-01-02796-21-001 (300 mg/50 mL) of 08.09.2022.
Storage
- Store below 25 °C, keep the vial in the outer carton to protect from light.
- After first opening (before dilution): 28 days at up to 25 °C; use the diluted solution immediately.
- The medicine is stored, prepared and disposed of by the healthcare institution in accordance with the regulations for cytotoxic medicines.
Frequently asked questions
How long does a Pataxel infusion take?
Usually 3 hours, and 24 hours in some ovarian cancer regimens. Cycles are usually repeated every 3 weeks, and every 2 weeks in Kaposi's sarcoma.
Why are other medicines given before the infusion?
Premedication with a corticosteroid, an antihistamine and an H2 antagonist reduces the risk of severe allergic reactions to paclitaxel and polyoxyl castor oil.
Will I lose my hair?
Hair loss is a very common side effect – in most patients it is marked and usually occurs in the first month of treatment.
Can I drive after treatment?
Not immediately after the infusion: the medicine contains alcohol (up to 21 g per average dose), and dizziness, nausea and fatigue may affect the ability to drive.
Sources
- ALIMS – Package leaflet Pataxel 30/100/300 mg (PIL, Serbian; 100 mg/16.7 mL authorisation)
- ALIMS – Summary of product characteristics Pataxel (SmPC, Serbian; 100 mg/16.7 mL authorisation)
- ALIMS – Package leaflet Pataxel (PIL, Serbian; 30 mg/5 mL authorisation)
- ALIMS – Package leaflet Pataxel (PIL, Serbian; 300 mg/50 mL authorisation)
Sources checked on: 25.10.2026.
Pharmacy Online has a contract with the Daily Express courier service and it is delivered on the territory of the Republic of Serbia through this service. Exports of goods to foreign countries are done through DHL and PostExport.
For all orders received up to 12h from Monday to Friday, the approximate delivery time is 2-4 business days for the whole territory of the Republic of Serbia. In case the order is placed on weekends (Saturdays and Sundays), the delivery is done as well as for the orders received on Monday - so next business day.
Deliveries are not made on Saturdays and Sundays.
Additional information
The items will be packed so that they cannot be damaged by normal handling of the goods in transit. When picking up the product, the buyer is obliged to check for any damage and immediately advertise it to the courier who delivered the goods, or refuse to take over the shipment, which shows the external damage. Any subsequent product claims for shipping damage will not be considered.
When picking up the product, the customer is required to sign the delivery note taken by the Daily Express delivery worker. The delivery note is considered to be a receipt and delivery note.
The courier service delivers the goods to the address, ie. does not bring into the living space.
Delivery restrictions on goods
Delivery of items purchased on the site www.apotekaonline.rs is made exclusively through the Daily Express courier service in the territory of the Republic of Serbia. Delivery outside the territory of the Republic of Serbia, ie export of goods, is done exclusively through the service of DHL and PostExport Post of Serbia.
Shipping cost
For the territory of the Republic of Serbia:
For goods ordered up to 5.000,00 RSD, delivery charge is 350.00 RSD (VAT included). For goods over 5.000,00 RSD, shipping is free of charge.
For international delivery:
For the export of goods abroad through the PostExport service of Post of Serbia, the shipping price is for:
- Zone I (Slovenia, Croatia, Bosnia and Herzegovina, Montenegro, Northern Macedonia) - 1,280.00 RSD
- Zone II (Other European countries) - 1,790.00 RSD
- Zone III (Asia, Africa, America, Australia and other countries) - 2,650.00 RSD
Delivery time is 15 days or more (depending on the country of delivery)
For export of goods abroad through DHL service, the shipping price is 2,700.00 RSD. Delivery time is 1-5 business days (depending on the country of delivery)
Shipping cost is with tax. The price includes the delivery of the parcel to the buyer's address with the associated tax and customs at the seller's expense. A possible additional cost may be a customs charge against the buyer, depending on the country to which the package is being shipped.
For any additional questions, complaints or checking the current location of your shipment, please contact us at the following e-mail address: info@apotekaonline.rs